nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Diazo- und Azoverbindungen der Fettreihe, Barth, Leipzig (1888) Studien mit Hydrazin, Barth, Leipzig, Bd 1,2 (1896), Bd 3,4 (1918) Einwirkung von Basen auf Diazoessigester, Berlin (1911) Die reduktion der aromatische Aldazine und Ketazine, Barth, Leipzig (1912) Hydrazide und Azide der Azidofettsäuren, Berlin (1912) Die Einwirkungen von Hydrazin auf Nitroverbindungen, Barth, Leipzig (1913) Buchner, E.; Curtius, Th. (1885). "Synthese von Ketonsäureäthern aus Aldehyden und Diazoessigäther". Berichte (in German). 18 (2): 2373–2377. doi:10.1002/cber.188501802118. Buchner, E.; Curtius, Th. (1885). "Ueber die Einwirkung von Diazoessigäther auf aromatische Kohlenwasserstoffe". Berichte (in German). 18 (2): 2377–2379. doi:10.1002/cber.188501802119. Curtius, Th. (1890). "Chemische Notizen". Berichte (in German). 23 (2): 3023–3041. doi:10.1002/cber.189002302233. Curtius, Th. (1894). "Hydrazide und Azide organischer Säuren I. Abhandlung". J. Prakt. Chem. (in German). 50 (1): 275–294. doi:10.1002/prac.18940500125.
Alcohol works in the brain primarily by increasing the effects of GABA (γ-aminobutyric acid), the major inhibitory neurotransmitter in the brain; by facilitating GABA's actions in the GABAA receptor, alcohol suppresses the activity of the central nervous system. Alcohol also directly affects a number of other neurotransmitter systems including those of glutamate, glycine, acetylcholine, and serotonin. The pleasurable effects of alcohol ingestion are the result of increased levels of dopamine and endogenous opioids in the reward pathways of the brain. After oral ingestion, ethanol is absorbed via the stomach and intestines into the bloodstream. Ethanol is highly water-soluble and diffuses passively throughout the entire body, including the brain. Soon after ingestion, it begins to be metabolized, 90% or more by the liver. One standard drink is sufficient to almost completely saturate the liver's capacity to metabolize alcohol. The main metabolite is acetaldehyde, a toxic carcinogen. Acetaldehyde is then further metabolized into ionic acetate by the enzyme aldehyde dehydrogenase (ALDH). Acetate is not carcinogenic and has low toxicity, but has been implicated in causing hangovers. Acetate is further broken down into carbon dioxide and water and eventually eliminated from the body through urine and breath. 5 to 10% of ethanol is excreted unchanged in the breath, urine, and sweat.
=== Alternative routes of administration === In rhesus macaques, BCG shows "unprecedented" rates of TB protection when given intravenously. Some risks must be evaluated before it can be translated to humans. The University of Oxford Jenner Institute is conducting a study comparing the efficacy of injected versus inhaled BCG vaccine in already-vaccinated adults.
== Significance == The label ‘open-source’ can provide real benefits to companies looking to hire top talent or attract customers. The debate around "openwashing” (or calling a project open-source when it is mostly closed) has big implications for the success of various projects within the industry. Open-source artificial intelligence tends to get more support and adoption in countries and companies that do not have their own leading AI model. These open-source projects can help to undercut the position of business and geopolitical rivals with the strongest proprietary models. Europe is a region pursuing openness as a digital sovereignty strategy to try and reduce the leverage that countries like the United States can use in negotiations on various topics like trade.
Sources: en.wikipedia.org
7-Acetoxymitragynine is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the South-East Asian tree known as kratom. It can be derived by acetylation of the hydroxyl group of 7-hydroxymitragynine, for instance with acetic anhydride, but can also be produced directly from mitragynine by reaction with Lead(IV) acetate. Unlike heroin, 7-acetoxymitragynine is less potent than 7-hydroxymitragynine, but nevertheless retains opioid activity. However It is not commonly or specifically found nor sold.
=== Uterine effects === Under normal physiological circumstances, progesterone secreted by the corpus luteum during the luteal phase of the menstrual cycle produces endometrial transformation of the estrogen-primed uterus in preparation for implantation and pregnancy. Normal progesterone production during the luteal phase is 25 mg/day on average with a range of 15 to 50 mg/day. Progesterone levels during the luteal phase range from 7 ng/mL to 22 ng/mL using liquid chromatography–tandem mass spectrometry (LC–MS/MS) per one source. Sustained progesterone levels of more than 5 ng/mL, perhaps approximately 10 ng/mL, are required for full endometrial transformation. Progesterone levels of more than 10 ng/mL are rarely associated with luteal-phase defect on the basis of endometrial biopsy. Luteal-phase levels of progesterone are said to be produced by 25 mg/day progesterone in oil solution by intramuscular injection or by 100 mg/day progesterone by vaginal or rectal administration. Progesterone by intramuscular injection in oil solution has been found to produce endometrial transformation at a dose of 10 or 20 mg/day for 14 days (total dose per cycle of 200 mg), whereas a single intramuscular injection of 200 mg progesterone in microcrystalline aqueous suspension provides endometrial transformation after 10 to 14 days. A study found full and equivalent endometrial transformation with subcutaneous injection of 25 mg/day versus 50 mg/day progesterone in aqueous solution.
The targets of the subpoenas are former White House Chief of Staff Mark Meadows, former White House Deputy Chief of Staff for Communications Dan Scavino, former Defense Department official Kashyap Patel and former Trump adviser Steve Bannon. September 24 The U.S. House votes to pass the Women's Health Protection Act, an abortion rights bill, in response to the Supreme Court refusing to block the Texas Heartbeat Act from becoming law. Fox News announces that it has banned Rudy Giuliani and his son Andrew Giuliani from appearing on the channel for three months. September 25 – A train derails in Montana, killing three people. September 26 – 2021 NFL season: Baltimore Ravens kicker Justin Tucker kicks a 66-yard field goal during the team's 19–17 victory against the Detroit Lions, making it the longest field goal in National Football League history. September 27 COVID-19 pandemic COVID-19 vaccination In Vermont, registration opens to people aged 75 years and older to receive the booster shot of the Pfizer–BioNTech COVID-19 vaccine. In Washington, D.C., President Biden receives his third dose of the COVID-19 vaccine. Grammy Award-winning singer R. Kelly is found guilty in a federal court on all counts of sexually abusing women and children over two decades. Ford announces an $11.4 billion plan for electric vehicle (EV) production, its largest ever investment in the US, with a major new factory in Tennessee and two battery parks in Kentucky creating nearly 11,000 jobs. September 29 – The U.S.
2(Ag(NH3)2)+ + RCHO + 2OH− → RCOOH + 2Ag + 4NH3. The size and shape of the nanoparticles produced are difficult to control and often have wide distributions. However, this method is often used to apply thin coatings of silver particles onto surfaces and further study into producing more uniformly sized nanoparticles is being done.
A number of security incidents are reported in London, Gatwick Airport and Chester, involving evacuations and anti-terror police. Queen Camilla misses the Royal Variety Performance because of "lingering post-viral" symptoms from her chest infection. 23 November The Ministry of Justice says it is aware of a data breach after details of the layouts of prisons in England and Wales were leaked to the dark web. Kensington Palace announces that the Princess of Wales has invited the families affected by the 2024 Southport stabbing to her annual Christmas carol service. It is reported that Andy Murray will coach his long-time former rival Novak Djokovic at the 2025 Australian Open. Less than five months after Labour won the 2024 general election, an online parliament petition calling for a new general election is launched and receives 200,000 signatures within its first six hours. 23–24 November – A number of yellow weather warnings for high winds and heavy rain are in place for Scotland, Northern Ireland, north Wales and northern England as Storm Bert arrives in the UK; there is also an amber alert for snow and ice in central Scotland. 24 November BBC News reports that businessman David Crisp, who was recorded telling an undercover reporter he was illegally selling luxury perfume to Russia, will not face criminal charges. An eight-year-old girl and a 34-year-old man are seriously injured in a shooting in Ladbroke Grove, West London. A 22-year-old man is arrested the following day on suspicion of attempted murder.
Sources: en.wikipedia.org
Isaiah Austin Javier Botet Austin Carlile Bradford Cox Euell Gibbons Flo Hyman Jonathan Jeanne Skinny Dennis Sanchez Vincent Schiavelli Troye Sivan John Tavener Chris Turner Matty Cardarople Other historical figures and celebrities have appeared on lists of people with Marfan syndrome, but from case to case the evidence is speculative, questionable, or refuted.
Creatine transporter deficiency (CTD) is an inborn error of creatine metabolism in which creatine is not properly transported to the brain and muscles due to defective creatine transporters. CTD is an X-linked disorder caused by mutation in SLC6A8. SLC6A8 is located at Xq28. Hemizygous males with CTD express speech and behavior abnormalities, intellectual disabilities, development delay, seizures, and autistic behavior. Heterozygous females with CTD generally express fewer, less severe symptoms. CTD is one of three different types of cerebral creatine deficiency (CCD). The other two types of CCD are guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency. Clinical presentation of CTD is similar to that of GAMT and AGAT deficiency. CTD was first identified in 2001 with the presence of a hemizygous nonsense change in SLC6A8 in a male patient.
with RAMP1: produces a CGRP receptor with RAMP2: produces an adrenomedullin (AM) receptor, designated AM1 with RAMP3: produces a dual CGRP/AM receptor designated AM2 These receptors are linked to the G protein Gs, which activates adenylate cyclase and activation results in the generation of intracellular cyclic adenosine monophosphate (cAMP). CGRP receptors are found throughout the body, suggesting that the protein may modulate a variety of physiological functions in all major systems (e.g., respiratory, endocrine, gastrointestinal, immune, and cardiovascular). The CGRP family of receptors including CALCRL can couple to G-protein Gαs, Gαi and Gαq subunits to transduce their signals. Furthermore binding of ligands to CALCRL can bias coupling to these G-protein. Peptide agonist bind to the extracellular loops of CALCRL. This binding in turn causes TM5 (transmembrane helix 5) and TM6 to pivot around TM3 which in turn facilitates Gαs binding.
== Financing and valuation == StoreDot raised over 6 million dollars in an initial investment round, and by the end of 2014 had raised another 42 million dollars. It raised another 62 million dollars by the end of 2017. The company was in negotiations in March 2021 for a SPAC merger at a $3.5 billion valuation. A further funding round of 70-80 million dollars in 2022 gave it a $1.5 billion valuation. The company plans as of 2023 to raise further capital in 2024 or 2025 in order to build up its silicon nanoparticles supply chain and secure dedicated manufacturing capacity for its batteries from existing manufacturers. StoreDot signed a SPAC merger in 2025 at a valuation of $800M. The merger was cancelled in 2026 after the company could not secure $30M in cash for its operations. Financial journalists estimated in February 2026 that StoreDot has funding for a few more months of operations.
Mabalirajan, Nahid Ali, Arun Bandyopadhyay, Aditya Konar, J. B. Chakraborty, I. C. Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, A. Manna, Roma Sinha, Pradyot Bhattacharya, J. Vinayagam, D. P. Jana, Sudeshna Chowdhury (January 2012). "Substituted catechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma (WO Patent 2,012,140,574.)". doi:10.13140/RG.2.1.2784.6488. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link) 1st Subhendu Bandyopadhyay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U. Mabalirajan, Nahid Ali, Arun Bandyopadhyay, Aditya Konar, J. Bagchi Chakraborty, I. Choudhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, A. Manna, Roma Sinha, Pradyot Bhattacharya, J. Vinayagam, D. P. Jana, Sudeshna Chowdhury (April 2011). "Inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma (Patent 1032DEL2011)". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.